| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 9.02M | 14.8M | 15.96M | 79.11M | 6.25M | 0 | 7.16M | 28.52M |
| Revenue Growth % | - | - | - | 0.64% | 0.08% | 3.96% | -0.92% | -1% | - | 2.98% |
| Cost of Goods Sold | 64.99K | 80.25K | 44.23M | 72.74M | 85.32M | 101.34M | 0 | 69.08M | 48.9M | 0 |
| COGS % of Revenue | - | - | 4.9% | 4.91% | 5.35% | 1.28% | - | - | 6.83% | - |
| Gross Profit | -64.99K | -80.25K | -35.21M | -57.94M | -69.36M | -22.23M | 6.25M | -69.08M | -41.74M | 28.52M |
| Gross Margin % | - | - | -3.9% | -3.91% | -4.35% | -0.28% | 1% | - | -5.83% | 1% |
| Gross Profit Growth % | - | -0.23% | -437.7% | -0.65% | -0.2% | 0.68% | 1.28% | -12.05% | 0.4% | 1.68% |
| Operating Expenses | 29.66M | 45.28M | 61.25M | 107.54M | 33.35M | 42.54M | 138.94M | 25.03M | 22.91M | 73.94M |
| OpEx % of Revenue | - | - | 6.79% | 7.26% | 2.09% | 0.54% | 22.22% | - | 3.2% | 2.59% |
| Selling, General & Admin | 11.3M | 12.19M | 17.02M | 34.8M | 34.86M | 36.86M | 28.78M | 23.93M | 22.91M | 18.01M |
| SG&A % of Revenue | - | - | 1.89% | 2.35% | 2.18% | 0.47% | 4.6% | - | 3.2% | 0.63% |
| Research & Development | 18.36M | 33.09M | 44.23M | 72.74M | 85.76M | 106.82M | 68.52M | 69.98M | 48.9M | 55.93M |
| R&D % of Revenue | - | - | 4.9% | 4.91% | 5.37% | 1.35% | 10.96% | - | 6.83% | 1.96% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -87.26M | -101.14M | 41.64M | -68.88M | -48.9M | 0 |
| Operating Income | -29.66M | -45.28M | -52.23M | -92.73M | -102.71M | -64.78M | -132.69M | -94.11M | -64.65M | -45.42M |
| Operating Margin % | - | - | -5.79% | -6.26% | -6.43% | -0.82% | -21.22% | - | -9.02% | -1.59% |
| Operating Income Growth % | -0.24% | -0.53% | -0.15% | -0.78% | -0.11% | 0.37% | -1.05% | 0.29% | 0.31% | 0.3% |
| EBITDA | -29.59M | -45.2M | -52.01M | -92.09M | -102.22M | -64.08M | -132.22M | -93.62M | -64.2M | -45.29M |
| EBITDA Margin % | - | - | -5.77% | -6.22% | -6.4% | -0.81% | -21.14% | - | -8.96% | -1.59% |
| EBITDA Growth % | -0.24% | -0.53% | -0.15% | -0.77% | -0.11% | 0.37% | -1.06% | 0.29% | 0.31% | 0.29% |
| D&A (Non-Cash Add-back) | 64.99K | 80.25K | 219.22K | 643K | 494K | 691K | 466K | 498K | 450K | 129K |
| EBIT | -29.66M | -44.88M | -52.23M | -92.73M | -104.22M | -59.09M | -91.05M | -93.01M | -64.65M | -45.42M |
| Net Interest Income | 0 | 0 | 983K | 3.08M | 4.3M | 2.62M | 302K | 1.02M | 3.45M | 5.57M |
| Interest Income | 1.23M | 1.54M | 983.21K | 3.08M | 4.3M | 2.62M | 302K | 1.02M | 3.45M | 5.57M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.2M | 398.77K | 368.2K | 3.08M | 5.85M | 2.62M | 302K | 1.02M | 3.45M | 5.57M |
| Pretax Income | -28.45M | -44.88M | -51.86M | -89.65M | -96.86M | -62.15M | -132.39M | -93.09M | -61.2M | -39.85M |
| Pretax Margin % | - | - | -5.75% | -6.06% | -6.07% | -0.79% | -21.17% | - | -8.54% | -1.4% |
| Income Tax | 0 | -617.67K | -9.05M | 1.1M | 774K | 0 | -2.53M | 0 | 33K | 330K |
| Effective Tax Rate % | 1% | 0.99% | 0.83% | 1.01% | 1.01% | 1% | 0.98% | 1% | 1% | 1.01% |
| Net Income | -28.45M | -44.26M | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M |
| Net Margin % | - | - | -4.75% | -6.13% | -6.12% | -0.79% | -20.76% | - | -8.55% | -1.41% |
| Net Income Growth % | -0.2% | -0.56% | 0.03% | -1.12% | -0.08% | 0.36% | -1.09% | 0.28% | 0.34% | 0.34% |
| Net Income (Continuing) | -28.45M | -44.26M | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.10 | -25.70 | -24.10 | -39.80 | -27.80 | -15.00 | -36.00 | -22.82 | -13.38 | -6.69 |
| EPS Growth % | 0.47% | -0.42% | 0.06% | -0.65% | 0.3% | 0.46% | -1.4% | 0.37% | 0.41% | 0.5% |
| EPS (Basic) | -18.10 | -25.70 | -24.10 | -39.80 | -27.80 | -15.00 | -36.00 | -22.82 | -13.38 | -6.69 |
| Diluted Shares Outstanding | 1.57M | 1.72M | 1.78M | 2.28M | 3.51M | 3.97M | 3.61M | 4.03M | 4.58M | 6M |
| Basic Shares Outstanding | 1.57M | 1.72M | 1.78M | 2.28M | 3.51M | 3.97M | 3.61M | 4.03M | 4.58M | 6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 68.37M | 53.57M | 123.12M | 222.5M | 282.78M | 224.49M | 154.2M | 96.97M | 133.79M | 115.5M |
| Cash & Short-Term Investments | 67.66M | 52.96M | 119.95M | 218.08M | 274.04M | 216.41M | 146.63M | 91.61M | 130.25M | 112.08M |
| Cash Only | 27.11M | 28.58M | 82.03M | 41.47M | 46.73M | 59.44M | 45.63M | 52.42M | 19.84M | 38.34M |
| Short-Term Investments | 40.56M | 24.39M | 37.91M | 176.61M | 227.31M | 156.97M | 101M | 39.19M | 110.41M | 73.73M |
| Accounts Receivable | 0 | 0 | 2.27M | 2.43M | 3.37M | 1.23M | 336K | 944K | 43K | 400K |
| Days Sales Outstanding | - | - | 92.03 | 59.91 | 77.15 | 5.68 | 19.61 | - | 2.19 | 5.12 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.2M | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.99M | 5.36M | 0 | 0 | 300K | 3.5M | 3.02M |
| Total Non-Current Assets | 65.38M | 44.54M | 46.18M | 45.54M | 65.11M | 58.76M | 36.86M | 4.83M | 3.04M | 3.67M |
| Property, Plant & Equipment | 148.61K | 214.69K | 860.03K | 557K | 13.8M | 10.73M | 7.18M | 3.94M | 2.72M | 3.35M |
| Fixed Asset Turnover | - | - | 10.49x | 26.58x | 1.16x | 7.37x | 0.87x | - | 2.63x | 8.51x |
| Goodwill | 12.64M | 12.64M | 12.64M | 12.64M | 12.64M | 12.64M | 0 | 0 | 0 | 0 |
| Intangible Assets | 29M | 29M | 29M | 29M | 29M | 29M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 23.39M | 2.44M | 3.35M | 0 | 0 | 0 | 27.97M | 0 | 0 | 0 |
| Other Non-Current Assets | 197.16K | 255.37K | 339.56K | 3.35M | 1.68M | 6.39M | 1.7M | 889K | 312K | 312K |
| Total Assets | 133.74M | 98.12M | 169.3M | 268.05M | 347.89M | 283.25M | 191.06M | 101.79M | 136.82M | 119.17M |
| Asset Turnover | - | - | 0.05x | 0.06x | 0.05x | 0.28x | 0.03x | - | 0.05x | 0.24x |
| Asset Growth % | 0.88% | -0.27% | 0.73% | 0.58% | 0.3% | -0.19% | -0.33% | -0.47% | 0.34% | -0.13% |
| Total Current Liabilities | 3.4M | 7.12M | 13.49M | 18.47M | 24.44M | 24.43M | 16.07M | 16.3M | 39.23M | 47.8M |
| Accounts Payable | 1.36M | 2.37M | 2.12M | 3.69M | 1.73M | 4.6M | 2.66M | 2.49M | 461K | 585K |
| Days Payables Outstanding | 7.66K | 10.77K | 17.53 | 18.53 | 7.4 | 16.56 | - | 13.17 | 3.44 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 3.19M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 | 1000K | 1000K |
| Other Current Liabilities | 0 | 0 | 6.85M | 4.67M | 7.8M | 7.02M | 6.43M | 599K | 1.15M | 9.13M |
| Current Ratio | 20.09x | 7.52x | 9.13x | 12.05x | 11.57x | 9.19x | 9.59x | 5.95x | 3.41x | 2.42x |
| Quick Ratio | 20.09x | 7.52x | 9.13x | 12.05x | 11.57x | 9.19x | 9.59x | 5.95x | 3.49x | 2.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 11.6M | 11.12M | 42.69M | 38.92M | 50.23M | 18.24M | 6.06M | 2.83M | 56.5M | 38.01M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 9.08M | 6.72M | 3.33M | 101K | 1.12M | 2.63M |
| Deferred Tax Liabilities | 11.6M | 11.12M | 2.14M | 3.25M | 10.51M | 2.53M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 108K | 0 | 0 | 0 | 2.73M | 0 | 35.38M |
| Total Liabilities | 15M | 18.24M | 56.18M | 57.39M | 74.67M | 42.68M | 22.13M | 19.13M | 95.73M | 85.81M |
| Total Debt | 0 | 0 | 0 | 0 | 12.27M | 10.13M | 6.48M | 3.46M | 2.34M | 3.09M |
| Net Debt | -27.11M | -28.58M | -82.03M | -41.47M | -34.46M | -49.31M | -39.15M | -48.95M | -17.5M | -35.26M |
| Debt / Equity | - | - | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.06x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 118.74M | 79.88M | 113.12M | 210.65M | 273.22M | 240.58M | 168.93M | 82.66M | 41.1M | 33.36M |
| Equity Growth % | 1.03% | -0.33% | 0.42% | 0.86% | 0.3% | -0.12% | -0.3% | -0.51% | -0.5% | -0.19% |
| Book Value per Share | 75.62 | 46.37 | 63.73 | 92.39 | 77.88 | 60.63 | 46.84 | 20.49 | 8.98 | 5.56 |
| Total Shareholders' Equity | 118.74M | 79.88M | 113.12M | 210.65M | 273.22M | 240.58M | 168.93M | 82.66M | 41.1M | 33.36M |
| Common Stock | 17.23K | 17.25K | 20.14K | 25K | 32K | 34K | 48K | 4K | 5K | 7K |
| Retained Earnings | -163.97M | -208.23M | -251.04M | -341.79M | -439.42M | -501.57M | -631.43M | -724.52M | -785.75M | -825.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -821.59K | -600.77K | -392.39K | -347K | -201K | -270K | -419K | -803K | -81K | -211K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.7M | -34.88M | 1.86M | -64.96M | -84.07M | -62.96M | -93.4M | -84.46M | 22.74M | -51.12M |
| Operating CF Margin % | - | - | 0.21% | -4.39% | -5.27% | -0.8% | -14.93% | - | 3.18% | -1.79% |
| Operating CF Growth % | -0.25% | -0.87% | 1.05% | -35.92% | -0.29% | 0.25% | -0.48% | 0.1% | 1.27% | -3.25% |
| Net Income | -28.45M | -44.26M | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M |
| Depreciation & Amortization | 64.99K | 80.25K | 219.22K | 643K | 494K | 691K | 466K | 498K | 450K | 129K |
| Stock-Based Compensation | 7.88M | 5.02M | 8.6M | 28.48M | 20.56M | 21.85M | 5.24M | 6.59M | 5.12M | 3.12M |
| Deferred Taxes | -7.85M | -617.67K | -9.05M | 1.1M | -774K | 0 | -2.53M | 0 | 0 | 0 |
| Other Non-Cash Items | 7.88M | 1.14M | 615.13K | -229K | 2.82M | 6.96M | 44.69M | 3.66M | 2.06M | -2.24M |
| Working Capital Changes | 1.79M | 3.75M | 44.28M | -4.21M | -9.53M | -30.31M | -11.4M | -2.12M | 76.34M | -11.95M |
| Change in Receivables | 0 | 0 | -2.27M | -156K | -944K | 2.14M | 894K | -608K | 901K | 43K |
| Change in Inventory | 0 | 0 | 1.1M | -601K | -3.01M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 456.1K | 1M | -244.19K | 1.57M | -1.96M | 2.87M | -1.94M | -166K | -2.03M | 124K |
| Cash from Investing | -64.86M | 36.2M | -15.64M | -135.4M | -50.32M | 68.07M | 26.52M | 90.64M | -69.14M | 40.17M |
| Capital Expenditures | -58.26K | -146.33K | -864.56K | -340K | -1.55M | -470K | -3.1M | -102K | -255K | -28K |
| CapEx % of Revenue | - | - | 0.1% | 0.02% | 0.1% | 0.01% | 0.5% | - | 0.04% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 150 | 36.2B | 33.18B | 48.88M | 1.74M | -1.75M | 857K | 0 | 24K | 0 |
| Cash from Financing | 81.57M | 152.64K | 67.24M | 159.79M | 139.65M | 7.6M | 53.06M | 614K | 13.82M | 29.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 554.27K | 0 | 0 | 4.37M | 4.99M | 2.15M | 258K | 289K | 129K | 155K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.76M | -35.03M | 995.52K | -65.3M | -85.62M | -65.18M | -96.49M | -84.56M | 22.49M | -51.15M |
| FCF Margin % | - | - | 0.11% | -4.41% | -5.36% | -0.82% | -15.43% | - | 3.14% | -1.79% |
| FCF Growth % | -0.24% | -0.87% | 1.03% | -66.59% | -0.31% | 0.24% | -0.48% | 0.12% | 1.27% | -3.27% |
| FCF per Share | -11.94 | -20.33 | 0.56 | -28.64 | -24.41 | -16.43 | -26.75 | -20.96 | 4.91 | -8.52 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.79x | -0.04x | 0.72x | 0.86x | 1.01x | 0.72x | 0.91x | -0.37x | 1.27x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 421K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -32.09% | -44.57% | -44.36% | -56.06% | -40.36% | -24.19% | -63.42% | -74% | -98.95% | -107.92% |
| Return on Invested Capital (ROIC) | -36.73% | -47.52% | -95.09% | -69.46% | -37.77% | -22.6% | -62% | -86.35% | -169.2% | -313.93% |
| Gross Margin | - | - | -390.37% | -391.36% | -434.51% | -28.1% | 100% | - | -582.67% | 100% |
| Net Margin | - | - | -474.66% | -613.02% | -611.63% | -78.57% | -2076.35% | - | -854.78% | -140.87% |
| Debt / Equity | - | - | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.06x | 0.09x |
| FCF Conversion | 0.66x | 0.79x | -0.04x | 0.72x | 0.86x | 1.01x | 0.72x | 0.91x | -0.37x | 1.27x |
| Revenue Growth | - | - | - | 64.15% | 7.83% | 395.55% | -92.09% | -100% | - | 298.16% |
Assembly Biosciences, Inc. (ASMB) reported $37.2M in revenue for fiscal year 2024.
Assembly Biosciences, Inc. (ASMB) grew revenue by 298.2% over the past year. This is strong growth.
Assembly Biosciences, Inc. (ASMB) reported a net loss of $38.5M for fiscal year 2024.
Assembly Biosciences, Inc. (ASMB) has a return on equity (ROE) of -107.9%. Negative ROE indicates the company is unprofitable.
Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $55.8M in fiscal year 2024, likely due to heavy capital investments.